Kitty Chui, Ph.D. Email & Phone Number

San Francisco, Ca, Us

• Assay development of immuno-qPCR add-on product: to develop a generic add-on chemical-conjugated oligonucleotides to lower the detection limits of secreted proteins from multi-cell type organoids such as hepatocytes-Hepatic Stellate cell-Kupffer-Liver Sinusoidal endothelial cell organoids to be used in conjunction with commercially available ELISA products.• In vitro cell-based assay development for characterization of human induced pluripotent stem cell iPSC-derived stem cell products.• Design and validate biomarkers of iPSC-derived cells sold by Tempo Bioscience, such as brain microvascular endothelial cells (BMEC), astrocytes, neurons, microglia, monocytes, macrophages, megakaryocytes, hepatocytes, cardiomyocytes, kidney cells etc. Techniques involved: gene expression by PCR, flow cytometry, fluorescent marker uptake, fluorescence microscopy, CYP functional protein activities in iHepatocytes.• Characterized blood brain barrier (BBB) model using iBMECs with known compound penetration and inhibitors for barrier functions and in vitro drug pharmacological assays such as various formats of antibodies.• Assay development of 3D 4-cell type hepatic organoid MASH model: inflammation by ELISAs.• Design for genotype DNA sequencing of custom patient-derived stem cell projects.• Design multiple gene primers and sequencing analysis of ALS patient DNA samples.• Provide cost estimation, assay grids, and R&D technical support including assay designs for custom-made client projects. For example, suggestion of using trogocytosis assay in 3D cancer organoid + iPSC-derived immune cell + lead cancer biologics drug.• Backup cell maintenance and cell banking.

2009, 2013-2014, 2015-2016

Sertoli Biology & Reproductive Function/Toxicology Applications:(1) Characterize human primary testicular derived sertoli cells; Sertoli cell product was launched and distributed via Lonza in 2009.(2) Develop in vitro 3-D reproductive toxicology assay platforms using human sertoli cells.Cancer Biology:(3) Preclinical Testing of truncated galectin-3C in multiple myeloma in vitro model for downstream animal modelNew Technology Platforms:(4) grant writing for human spermatogonial stem cells, HTS screening for multiple myeloma.(5) Scientific Advice / Assist in MandalMed's incubator operation.

(1) Reconstruct in vitro skin product AccuSkin used as an alternative test platform for pharmaceutical and/or cosmetic irritancy, toxicological and efficacy test.(2) Expand Xgene's patented technology to construct AccuCornea from human primary corneal epithelial cells and keratocyes to develop pilot alternative platform for Draize test.(3) Assay Development: a) Fluorescent cell labeling - trace specialty input cells within AccuOrgan. b) Non-invasive QC process to assess 3-D tissue integrity prior to release c) collaborate with external scientists to examine the compatibility of incorporating embryonic and adult stem cells, telomerase cells, other cell lines into current AccuSkin, AccuGraft, and AccuCornea platforms.

Wilmington, Nc, Us